Alnylam Pharmaceuticals (LTS:0HD2) Current Deferred Revenue: $4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HD2 Alnylam Pharmaceuticals Inc LTS:0HD2
62 GF Score
Price $218.14
GF Value $517.21
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Alnylam Pharmaceuticals Current Deferred Revenue?

Alnylam Pharmaceuticals LTS:0HD2 +6.82% 62 Current Deferred Revenue is $4 Mil as of Jun. 2026. GuruFocus rates LTS:0HD2 with a GF Score™ of 62/100 and a GF Value™ of $517.21 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Alnylam Pharmaceuticals's current deferred revenue for the quarter that ended in Jun. 2026 was $4 Mil.

Alnylam Pharmaceuticals Current Deferred Revenue Related Terms

Alnylam Pharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals Current Deferred Revenue Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 149.48 42.11 102.75 55.48 4.85

Alnylam Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.08 2.54 4.85 3.21 4.01
LTS:0HD2
62GF Score
Alnylam Pharmaceuticals Inc LTS:0HD2
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $4 Mil mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Current Deferred Revenue of $4 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Current Deferred Revenue too high?
Alnylam Pharmaceuticals' current Current Deferred Revenue is $4 Mil. Overall, Alnylam Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Current Deferred Revenue compare to ONC and RVMD?
Alnylam Pharmaceuticals' Current Deferred Revenue of $4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Current Deferred Revenue is $4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $517.21, compared to a current price of $218.14 — trading 57.8% below its estimated fair value. The current Current Deferred Revenue is $4 Mil. Alnylam Pharmaceuticals' overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Current Deferred Revenue is $4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of $218.14 is trading 57.8% below its estimated GF Value™ of $517.21. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for LTS:0HD2:

  • Current Deferred Revenue: $4 Mil
  • GF Value™: $517.21 vs. price of $218.14 (57.8% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
62GF Score

Get the complete analysis for LTS:0HD2

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$218.14
Price
$517.21
GF Value